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ABSTRACT
Objective: The novel synergistic drug candidate CRx-102
comprises dipyridamole and low dose prednisolone and is
in clinical development for the treatment of immunoin-
flammatory diseases. The purpose of this clinical study
was to examine the efficacy and safety of CRx-102 in
patients with hand osteoarthritis (HOA).
Methods: The study was conducted as a blinded,
randomised, placebo-controlled trial at four centres in
Norway. Eligibility criteria included being of age 30–70
years, at least one swollen and tender joint, a Kellgren–
Lawrence (K–L) score of 2 or higher on radiographs, and a
score of at least 30 mm pain on the Australian/Canadian
Osteoarthritis Hand Index (AUSCAN) visual analogue pain
scale (VAS). The primary endpoint was a reduction in pain
from baseline to day 42 on the AUSCAN pain subscale.
Two-sided p values for the differences in least squares
(LS) means adjusted for baseline are presented.
Results: The mean age of the 83 patients with HOA was
60 years and 93% were females. CRx-102 was
statistically superior to placebo at 42 days for changes in
AUSCAN pain (LS mean 214.2 vs 24.0) and for clinically
relevant secondary endpoints (joint pain VAS (218.6 vs
26.3), patient global VAS (215.9 vs 24.2)) in the
intention to treat population. The most frequently reported
adverse event during the study was headache (52% in
CRx-102 vs 15% in the placebo group).
Conclusions: The novel synergistic drug candidate CRx-
102 demonstrated efficacy by statistically reducing pain
compared to placebo in HOA and was generally well
tolerated.
Osteoarthritis (OA) is the most common rheu-
matic joint disease. It is reported to be more
prevalent than all other forms of arthritis, and this
prevalence seems to be increasing.
1 The typical
clinical manifestations are pain, stiffness and
physical disability. Localised loss of hyaline articu-
lar cartilage and adjacent bone remodelling are the
key structural changes of OA, and local inflamma-
tion may also contribute to the pain and joint
damage.
2
Knee OA is the most common form of the
disease, followed by hand OA (HOA).
3 The
majority of people aged 55 years and over have
radiographic changes of OA in at least one hand
joint and approximately one-fifth of this popula-
tion has symptomatic HOA.
45The prevalence of
HOA increases with age and is higher in females
than in males.
4 Recent studies also indicate that
the burden of disease for patients with HOA is
considerable across a variety of dimensions of
health-related quality of life.
6
Non-steroidal anti-inflammatory drugs
(NSAIDs), including selective cyclo-oxygenase-2
(COX-2) inhibitors are important symptom-
modifying therapeutic options for patients with
OA.
7–10 However, NSAIDs are associated with risk
of gastrointestinal adverse events and the selective
COX-2 inhibitors have come under special scrutiny
because of cardiovascular adverse effects.
11 12
Similar concerns have recently been raised about
the cardiovascular safety of non-naproxen
NSAIDs,
13 and the efficacy of long-term dosing of
NSAIDs in knee OA has also been questioned.
14
Few controlled clinical trials have addressed the
efficacy of pharmacological therapies in HOA and,
in particular, few controlled studies have included
a placebo group.
10 15 Thus, there is an obvious need
to document the efficacy of existing drugs and, in
particular, to identify new and effective agents for
patients with HOA.
16
Corticosteroids are a mainstay of effective anti-
inflammatory therapy in many clinical settings,
but the side effects associated with chronic
administration have limited their use in OA to
occasional intra-articular administration. It has
long been a goal to develop a therapeutic agent
with the anti-inflammatory and disease modifying
activities of corticosteroids without their asso-
ciated side effects.
17 One approach to creating such
a therapeutic agent is to develop a drug combina-
tion that contains a glucocorticoid and an enhan-
cing agent that pair synergistically to generate a
powerful anti-inflammatory effect. Synergistic
combinations can have an effect that is greater
and more selective than the sum of the activities of
the individual components, and thus can provide
greater therapeutic benefit with lower toxicity.
Synergy is often observed in multi-target thera-
peutics that modulate the activity of two or more
molecular targets to create a novel therapeutic
action.
18 19 In vivo models testing anti-inflamma-
tory combinations containing a low dose steroid
have demonstrated a synergistic interaction
between the steroid and the enhancing agent that
produces an effect equivalent to that of a high dose
steroid alone, without indications of high dose
steroid side effects.
CRx-102 is one such novel synergistic drug
candidate and is in clinical development for the
treatment of immunoinflammatory diseases
including rheumatoid arthritis (RA) and OA. This
drug candidate comprises a combination of a low
dose of prednisolone (3 mg) and 200 or 400 mg
dipyridamole. According to results from pre-clinical
pharmacology experiments, CRx-102 works
through a novel mechanism of action by which
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matory and immunomodulatory effects without replicating
steroid side effects.
20–22 The objective of the current phase 2
study was to evaluate the efficacy and safety of the novel
synergistic drug candidate CRx-102 compared to placebo in
patients with HOA over a 6-week dosing period.
MATERIALS AND METHODS
Study population
Males and females between the ages of 30 and 70 years with
HOA, as defined by the American College of Rheumatology
(ACR) criteria,
23 were enrolled in the study. Additional inclusion
criteria included presence of more than one swollen joint and
more than one tender joint, a Kellgren–Lawrence (K–L) score of
two or more on radiographs and self-reported hand pain that
had to be at least 30 mm on the Australian/Canadian
Osteoarthritis Hand Index (AUSCAN) visual analogue scales
(VAS).
24 25 All subjects had to sign and date an informed
consent. The regional ethics committee evaluated the study, the
storage and analyses of data was licensed from the data
inspectorate and approval for the collection of biologic material
was obtained from the Department of Health.
Subjects who were pregnant, lactating or using hormonal
birth control pills as well as subjects with a history of
hypersensitivity to corticosteroids and/or dipyridamole, taking
bisphosphonates or who had a positive rheumatoid factor test
were excluded from the study. Furthermore, subjects who had
taken any corticosteroids orally, topically or intra-articularly 3
months prior to enrolment were also excluded. Other exclusion
criteria included a history of asthma, HIV infection, hepatitis,
currently uncontrolled diabetes, use of statins in a dose that had
changed during the prior 3 months, known active infection or a
surgical procedure within 30 days of study initiation. Since one
of the components of CRx-102 is dipyridamole, patients on
warfarin, ticlopidine, clopidogrel or aspirin of more than 81 mg
daily were also excluded from entering the study.
Design and medication
The study was designed as a 6-week randomised, blinded,
placebo-controlled four-centre parallel group study. Within
2 weeks of a screening visit, patients who fulfilled the eligibility
criteria were randomly assigned to CRx-102 or placebo. Follow-
up assessments were performed after 7, 14, 28 and 42 days, with
a final safety visit after approximately 56 days.
A total of 83 subjects were randomised 1:1 to a daily dose
regimen of either CRx-102 or placebo. CRx-102 for days 1–7
combined 2 mg of prednisolone with 100 mg of dipyridamole at
8am and 1 mg of prednisolone with 100 mg of dipyridamole at
1pm. From days 8–42 CRx-102 combined 2 mg prednisolone
with 200 mg of dipyridamole at 8 am and 1 mg of prednisolone
Figure 1 Flow chart of the selection of
patients for this study and patient
disposition.
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group received an equal number of tablets, dosed at the same
time of day as for the test compound and all containing placebo.
Paracetamol was provided as rescue medication throughout
the study at a daily dose of up to 4000 mg, and the usage was
recorded. The use of NSAIDs in all subjects was stopped for the
duration of the study starting at the initial screening visit.
Assessments
The AUSCAN
24 25 was used as the primary assessment tool.
Previous studies have demonstrated that this instrument has
acceptable reliability, construct validity and responsiveness. The
translated Norwegian version has also satisfactory clinimetric
properties.
26 We chose to use the version with responses on VAS
to each item. AUSCAN has five items measuring pain, one
measuring stiffness and nine measuring physical function.
The pain and physical functioning scores were normalised to a
0–100-point scale prior to the analyses.
Additional patient-reported measures included a joint pain
VAS (question: how would you describe the intensity of your
joint pain during the last 2 days?) and global assessment VAS
(question: we ask you to evaluate the activity of your
osteoarthritis over the last 2 days. When you take all symptoms
into consideration, how will you evaluate your condition?). The
patients did not have access to scores from previous visits when
they were performing each subsequent assessment.
The patients were clinically examined for vital signs at each
visit and each individual finger joint (distal interphalangeal
(DIP), proximal interphalangeal (PIP), metacarpophalangeal
(MCP) and carpometacarpal (CMC)) on the right and left hand
was examined for the presence of joint tenderness, soft tissue
swelling, bony enlargement and limited joint motion. A score
was calculated using the number of PIP and DIP joints for the
presence of each of these four characteristics (ie, score range 0–
18 for each).
Sera were frozen and stored and later analysed with a high
sensitivity technique to determine levels of C-reactive protein
(CRP). Regular blood chemistry, including fasting blood glucose,
was recorded. Unsolicited adverse events were also recorded.
Analyses
AUSCAN pain was the predefined primary endpoint. The
sample size was calculated based on an assumed improvement
of 20% in AUSCAN pain VAS in the CRx-102 group compared
to a 10 % improvement in the placebo-group from baseline to
day 42 with an alpha of 0.05%, to achieve 80% power assuming
a 15% drop out rate using a one tailed t test for the comparison
of the mean changes.
The primary analysis was conducted on the intention to treat
(ITT) population that included all patients who took at least
one dose of study medication. Secondarily, an analysis was
performed in the per-protocol population, which was defined as
all subjects who received at least one dose of study medication,
had no major protocol violations and had a study drug
compliance of at least 75%. The treatment effects were derived
from analysis of covariance (ANCOVA) adjusting for the
baseline values. These analyses tested the difference (with
95% confidence intervals) between these adjusted mean changes
in the active drug compared to the placebo group from baseline
to 42 days. The last non-missing post-baseline observation was
carried forward (LOCF) to replace subsequent missing values.
Two-sided p values for the differences in least square means
adjusted for baseline are presented (the study protocol
recommended use of one-sided tests, but we found it more
Table 1 Demographic variables and joint involvement (mean (SD)) for
continuous variables, percentages for counts)
CRx-102 (n=42) Placebo (n=41)
Age 61.1 (5.0) 59.6 (5.3)
Female 93 93
Caucasian 100 100
Height, cm 166.0 (6.7) 167.7 (8.2)
Weight, kg 71.1 (12.0) 74.5 (14.6)
Percentage with OA joint
involvement:
Right MTP joint I 36 10
Left MTP joint I 33 10
Lumbar spine 24 17
Cervical spine 19 7
Right hip 17 10
Left hip 10 12
Right knee 19 7
Left knee 17 10
Other joints 17 15
Finger joints: percentage with
radiographic grade 2–4 K–L score:
Minimal (2) 14 12
Moderate (3) 45 32
Severe (4) 40 56
K–L, Kellgren–Lawrence; MTP, metatarsophalangeal; OA, osteoarthritis.
Table 2 Baseline mean (SD) values of efficacy variables, adjusted mean changes from baseline to day 42 (least squares mean (standard error of
mean)) and treatment effect (mean difference (95% CI) placebo minus CRx-102) in the intention to treat population
Baseline Changes
Treatment effect p Value CRx-102 (n=42) Placebo (n=41) CRx-102 Placebo
AUSCAN:
Pain 57.9 (20.2) 60.9 (19.4) 214.2 (3.0) 24.0 (3.1) 10.2 (1.6 to 18.7) 0.020
Physical 62.4 (19.5) 67.8 (17.5) 28.1 (2.7) 23.6 (2.7) 4.5 (23.2 to 12.2) 0.246
Stiffness 61.1 (18.0) 64.5 (21.2) 215.2 (3.2) 27.7 (3.3) 7.5 (21.7 to 16.7) 0.108
VAS:
Joint pain 58.3 (20.1) 62.1 (16.9) 218.6 (3.3) 26.3 (3.3) 12.3 (3.0 to 21.5) 0.010
Patient global 58.0 (19.5) 62.3 (17.9) 215.9 (3.2) 24.2 (3.3) 11.7 (2.5 to 20.8) 0.013
Lab tests:
CRP mg/litre 2.5 (2.9) 2.3 (2.2) 20.2 (0.4) 0.1 (0.4) 0.3 (20.7 to 1.4) 0.536
Joint counts:
Tender joints 9.5 (4.7) 9.4 (4.6) 23.6 (0.7) 22.4 (0.7) 1.2 (20.9 to 3.2) 0.258
Soft tissue swelling 5.5 (4.7) 5.0 (4.4) 22.4 (0.5) 21.6 (0.5) 0.8 (20.6 to 2.2) 0.262
AUSCAN, Australian/Canadian Osteoarthritis Hand Index; CRP, C-reactive protein; VAS, visual analogue scale.
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approach, in this work). The statistical analyses were performed
by the sponsor in collaboration with the principal investigator
(TKK).
RESULTS
A total of 83 patients (77 (93%) females) with a mean (standard
deviation (SD)) age of 60.4 (5.2) years were enrolled into
the study. A Consolidated Standards of Reporting Trials
(CONSORT) flow-chart is shown in fig 1. The study groups
were comparable for demographic characteristics (table 1). The
patients in the active treatment group had wider OA joint
involvement (table 1), but the baseline levels of pain and
physical limitations were comparable (table 2).
A significant difference (p=0.020) in the AUSCAN pain score
(the primary endpoint) at the end of the study was demon-
strated in favour of CRx-102 compared to placebo in the ITT
population (table 2). CRx-102 was also statistically superior to
placebo at 42 days for joint pain VAS and patient global VAS
(table 2). Figure 2 displays how the improvement developed
over time and also that the differences between CRx-102 and
placebo were discernible after 2 weeks. The comparison
between CRx-102 and placebo in the per-protocol population
was also consistently in favour of CRx-102 (table 3).
The tender and swollen joint counts of the 18 PIP and DIP
joints were numerically improved in the CRx-102 group
compared to placebo (table 2) and the group differences
approach statistical significance in the per-protocol population
(table 3). The counts of joints with limited motion and bony
swelling did not change during the study (data not shown).
The proportions of patients reporting at least one adverse
event in the CRx-102 and placebo groups were 64% and 32%,
respectively. The most common adverse event in both groups
was headache, which was more frequently reported in the CRx-
102 group (52%) than in the placebo group (15%). A total of
21% of the patients in the CRx-102 group also reported nausea,
versus none in the placebo group (table 4). No serious adverse
events were reported in the CRx-102 group. Discontinuation
occurred more often in the CRx-102 (n=16, 38%) than in
placebo group (n=6, 15%) (fig 1) and was mostly due to
headache. Most of the discontinuations occurred early in the
study (fig 3).
DISCUSSION
HOA is a frequent disease in people more than 60 years of age
and imparts a considerable disease burden, on the individual
6
and in society.
2 However, few studies have formally addressed
the efficacy of symptom-modifying drugs in HOA.
10 15 This
phase 2 study demonstrated that CRx-102, a combination of
a low dose prednisolone and a titrated dose of dipyridamole,
was superior to placebo across a variety of patient-reported
measures.
Figure 2 Mean improvements from baseline adjusted for baseline values Australian/Canadian Osteoarthritis Hand Index (AUSCAN) pain (A), AUSCAN
stiffness (B), AUSCAN physical (C), pain visual analogue scale (VAS) (D) and global VAS (E) in patients receiving CRx-102 and placebo (intention to
treat population) with one-sided p values for the differences of adjusted least square means.
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carpometacarpal (CMC) joint are particularly affected,
27 but
patients with HOA tend to have involvement of multiple joints,
a condition that is often referred to as generalised OA.
28 The
joints most frequently involved in this study population were
the first metatarsophalangeal (MTP) joint, the knee and
additionally the lumbar and cervical spine (table 1). We do
not know how CRx-102 influenced these other joint areas, since
we were not measuring low back pain, pain in the big toe or
were not using the Western Ontario and McMaster Universities
(WOMAC) index,
29 a specific measure of knee and hip OA.
However, the question on joint pain did not specifically address
pain in the finger joints and the clear differentiation between
CRx-102 and placebo for this measure may indirectly support
an efficacy that goes beyond the finger joints.
Inflammation has been recognised as a feature of the disease
process in OA.
30–33 A synergistic drug candidate such as CRx-102
comprises two components that are designed to act synergisti-
cally through multiple pathways, providing a novel therapeutic
effect thatneither component canachieveontheirown. CRx-102
has been shown to have strong anti-inflammatory effects in
preclinical assays with a greater average percentage inhibition of
tumour necrosis factor alpha (TNFa) and interleukin 1 (IL1)
release from human blood buffy coat cells than the inhibition
seen with each of the single agents alone.
20 Similarly, in the rat
model of lipopolysaccharide (LPS)-induced TNFa release, the
inhibition of release was greater with CRx-102 than the
individual components.
21 This finding was replicated in the rat
models of adjuvant and collagen-induced arthritis.
21
The preclinical studies on the mechanism of action of CRx-
102 indicate that CRx-102 acts through multiple molecular
pathways to create a synergistic immunomodulatory effect
without amplifying traditional glucocorticoid-associated side
effects. Additionally, the components of CRx-102 affect the
activity of key transcription factors, but not their nuclear
localisation nor does it increase glucocorticoid receptor translo-
cation or transcription from positive glucocorticoid response
element promoters relative to low dose prednisolone on its
own.
22 Dipyridamole may contribute to the action of CRx-102
by increasing cAMP in part though inhibition of phosphodies-
terases relevant to inflammation, as well as through modulating
adenosine transport resulting in increased extra-cellular endo-
genous adenosine.
34 Adenosine can suppress the release of TNFa
from activated monocytes and macrophages, but a small
placebo-controlled study was unable to demonstrate clinical
improvement following treatment with dipyridamole.
35
This study used the pain dimension in AUSCAN as the
primary endpoint, but also included an assessment of two other
core measures, function and patient global assessment.
36 37
AUSCAN has been developed as a disease-specific patient-
reported measure in hand OA. Development of the AUSCAN
HOA index was based on the questions and experience from the
WOMAC
38 as well as information from patient interviews.
24
AUSCAN was later validated in separate studies
25 and has also
been validated in the Norwegian language.
26 Consistent with
the present findings, Allen et al
39 showed that the AUSCAN
index can reliably measure changes in pain, stiffness and
function, thereby providing a meaningful endpoint for clinical
trials in HOA. For feasibility reasons we chose not to include
Figure 3 Time from dose 1 to withdrawal from the treatment (intention
to treat (ITT) population, Kaplan–Meier plot).
Table 3 Baseline mean (SD) values of efficacy variables, adjusted mean changes from baseline to day 42 (least squares mean (SEM)) and treatment
effect (mean difference (95% CI) placebo minus CRx-102) in the per-protocol population
Baseline Changes
Treatment effect p Value CRx-102 (n=26) Placebo (n=33) CRx-102 Placebo
AUSCAN:
Pain 61.9 (16.6) 63.8 (17.2) 220.5 (4.1) 26.2 (3.7) 14.3 (3.2 to 25.5) 0.012
Physical 64.9 (18.9) 70.9 (15.5) 212.9 (3.7) 25.9 (3.2) 7.0 (22.9 to 16.8) 0.061
Stiffness 62.9 (17.4) 67.8 (19.8) 220.3 (4.4) 28.3 (3.9) 12.0 (0.2 to 23.9) 0.047
VAS:
Joint pain 59.8 (19.5) 62.9 (16.7) 223.5 (4.4) 26.3 (3.9) 17.2 (5.5 to 28.9) 0.005
Patient global 61.5 (17.5) 62.5 (17.6) 223.4 (4.0) 24.6 (3.6) 18.8 (8.1 to 29.5) 0.001
Lab tests:
CRP mg/litre 2.0 (1.8) 2.3 (2.2) 20.2 (0.5) 0.4 (0.4) 0.6 (20.7 to 1.8) 0.364
Joint counts:
Tender joints 9.6 (4.8) 9.8 (4.7) 25.0 (1.0) 22.6 (0.9) 2.4 (20.3 to 5.0) 0.083
Soft tissue swelling 5.6 (4.6) 4.9 (4.3) 23.1 (0.6) 21.9 (0.5) 1.3 (20.3 to 2.8) 0.116
AUSCAN, Australian/Canadian Osteoarthritis Hand Index; CRP, C-reactive protein; VAS, visual analogue scale.
Table 4 Most commonly reported adverse events (AE) (>5% of total subjects) in the intention to treat (ITT) population (no. of patients (%))
CRx-102 (n=42) Placebo (n=41) Total (n=83)
Subjects with at least one AE 27 (64) 13 (32) 40 (48)
Headache 22 (52) 6 (15) 28 (34)
Nausea 9 (21) 0 9 (11)
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assessment of HOA.
40 41
The patients had to stop treatment with NSAIDs and
paracetamol at the screening visit, but a disease flare was not
required for inclusion in the study. We unfortunately did not
capture detailed information about ongoing medication at the
screening visit, and we do not have detailed data on the changes
in efficacy endpoints from screening to randomisation.
In rheumatoid arthritis, several composite disease measures
have been developed over the past years, and these are most
often based on joint counts. Similar composite disease specific
measures do not exist in HOA. We examined the number of
finger joints with tenderness, soft tissue swelling, limited
motion and bony swelling at baseline and during follow-up. It
is reasonable to assume that tenderness and soft tissue swelling
at least in part reflect the inflammatory component of the
disease. Joint counts were numerically improved in the CRx-102
treatment group compared to the placebo group (tables 3 and
4). The number of joints with bony swelling did not change
during the study; this endpoint was not expected to be
influenced by anti-inflammatory therapy. More research is
needed to address the development of joint count-indices for
HOA that are valid, reliable and responsive.
Headache was the most commonly reported adverse event in
this trial and was most frequently observed during the first days
of treatment (table 4 and fig 3). This type of headache has
previously been associated with dipyridamole administration
42
and also with other cardiovascular pharmaceutical products
with vasodilatating properties. As in the current study, these
headaches typically occur during the first days of treatment.
42
This early and high withdrawal rate is a potential limitation of
CRx-102. Thus, formulation development is necessary to
optimise the synergistic benefits of CRx-102 demonstrated in
this and other phase 2 studies and to minimise the observed
incidence of headache. The objective of the formulation should
be to deliver pulsed-doses of prednisolone with concurrently
releasing dipyridamole at a rate that maintains the anti-
inflammatory synergy and minimises the vasodilator effects
that are known to cause headaches.
In summary, preclinical studies have supported that the
synergistic drug candidate CRx-102, comprised of dipyramidole
and low dose prednisolone, has biological effects that exceed the
effects of each individual component. This placebo-controlled
phase 2 study suggests that the combination is effective in
patients with HOA. Follow-up studies should be initiated to
compare the clinical effects of CRx-102 versus the individual
components in HOA and other rheumatic joint diseases.
Funding: This study was funded by CombinatoRx Inc, the producer of CRx-102.
Competing interests: MN, YZ and JL are employees of CombinatoRx Inc, the
producer of CRx-102. The statistical analyses were performed by the sponsor in
collaboration with the principal investigator (TKK).
Ethics approval: The regional ethics committee evaluated the study, the storage and
analyses of data was licensed from the data inspectorate, and approval for the
collection of biologic material was obtained from the Department of Health.
REFERENCES
1. Ehrlich GE. The rise of osteoarthritis. Bull World Health Organ 2003;81;630.
2. Petersson IF, Jacobsson LT. Osteoarthritis of the peripheral joints. Best Pract Res
Clin Rheumatol 2002;16:741–60.
3. Oliveria SA, Felson DT, Reed JI, Cirillo PA, Walker AM. Incidence of symptomatic
hand, hip, and knee osteoarthritis among patients in a health maintenance
organization. Arthritis Rheum 1995;38:1134–41.
4. Zhang Y, Niu J, Kelly-Hayes M, Chaisson CE, Aliabadi P, Felson DT. Prevalence of
symptomatic hand osteoarthritis and its impact on functional status among the
elderly: The Framingham Study. Am J Epidemiol 2002;156;1021–7.
5. Dahaghin S, Bierma-Zeinstra SM, Ginai AZ, Pols HA, Hazes JM, Koes BW.
Prevalence and pattern of radiographic hand osteoarthritis and association with pain
and disability (the Rotterdam study). Ann Rheum Dis 2005;64:682–7.
6. Slatkowsky-Christensen B, Mowinckel P, Loge JH, Kvien TK. Health related quality
of life in females with symptomatic hand osteoarthritis – a comparison with female
rheumatoid arthritis patients, healthy controls and normative data. Arthritis Rheum
2007;57:1404–9.
7. Zhang W, Doherty M, Arden N, Bannwarth B, Bijlsma J, Gunther KP, et al. EULAR
evidence based recommendations for the management of hip osteoarthritis: report of
a task force of the EULAR Standing Committee for International Clinical Studies
Including Therapeutics (ESCISIT). Ann Rheum Dis 2005;64:669–81.
8. Wegman A, van der WD, van Tulder M, Stalman W, de Vries T. Nonsteroidal
antiinflammatory drugs or acetaminophen for osteoarthritis of the hip or knee? A
systematic review of evidence and guidelines. J Rheumatol 2004;31:344–54.
9. Jordan KM, Arden NK, Doherty M, Bannwarth B, Bijlsma JW, Dieppe P, et al. EULAR
recommendations 2003: an evidence based approach to the management of knee
osteoarthritis: report of a task force of the Standing Committee for International
Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2003; 62:1145–55.
10. Zhang W, Doherty M, Leeb BF, Alekseeva L, Arden NK, Bijlsma JW, et al. EULAR
evidence based recommendations for the management of hand osteoarthritis – report
of a task force of the Eular Standing Committee for International Clinical Studies
Including Therapeutics (ESCISIT). Ann Rheum Dis 2007;66:377–88.
11. Bresalier RS, Sandler RS, Quan H, Bolognese JA, Oxenius B, Horgan K, et al.
Cardiovascular events associated with rofecoxib in a colorectal adenoma
chemoprevention trial. N Engl J Med 2005;352:1092–102.
12. Solomon SD, McMurray JJ, Pfeffer MA, Wittes J, Fowler R, Finn P, et al.
Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma
prevention. N Engl J Med 2005;352:1071–80.
13. McGettigan P, Henry D. Cardiovascular risk and inhibition of cyclooxygenase: a
systematic review of the observational studies of selective and nonselective inhibitors
of cyclooxygenase 2. JAMA 2006;296:1633–44.
14. Bjordal JM, Ljunggren AE, Klovning A, et al. Non-steroidal anti-inflammatory drugs,
including cyclo-oxygenase-2 inhibitors, in osteoarthritic knee pain: meta-analysis of
randomised placebo controlled trials. BMJ 2004;329:1317.
15. Maheu E, Altman RD, Bloch DA, Doherty M, Hochberg M, Mannoni A, et al. Design
and conduct of clinical trials in patients with osteoarthritis of the hand:
recommendations from a task force of the Osteoarthritis Research Society
International. Osteoarthritis Cartilage 2006;14:303–22.
16. Kloppenburg M, Stamm T, Watt I, Kainberger F, Caston TE, Birrell FN, et al.
Research in hand osteoarthritis: time for reappraisal and demand for new strategies.
Ann Rheum Dis 2007;66: 1157–61.
17. Rhen T, Cidlowski JA. Antiinflammatory action of glucocorticoids – new mechanisms
for old drugs. N Engl J Med 2005;353:1711–23.
18. Keith CT, Borisy AA, Stockwell BR. Multicomponent therapeutics for networked
systems. Nat Rev Drug Discov 2005;4:71–8.
19. Zimmermann GR, Lehar J, Keith CT. Multi-target therapeutics: when the whole is
greater than the sum of the parts. Drug Discov Today 2007;12:34–42.
20. Borisy AA, Elliott PJ, Hurst NW, Lee MS, Lehar J, Price ER, et al. Systematic
discovery of multicomponent therapeutics. Proc Natl Acad Sci USA
2003;100:7977–82.
21. Elliott PJ, Keegan M, Avery W, Borisy AA. Crx-102: A novel, orally available,
syncretic agent with significant in vitro and in vivo immuno-modulatory activity and a
dissociated steroid profile. Arthritis Rheum 2004;50(Suppl):S370–1.
22. Price ER, Manivasakam P, Robinson E, Slanonic M, Nolan G, Smith B, et al.
Molecular insight into steroid dissociation of crx-102, a clinically active
immunomodulatory agent. Arthritis Rheum 2006;54(Suppl):S592.
23. Altman R, Alarcon G, Appelrouth D, Bloch D, Borenstein D, Brandt K, et al. The
American College of Rheumatology criteria for the classification and reporting of
osteoarthritis of the hand. Arthritis Rheum 1990;33:1601–10.
24. Bellamy N, Campbell J, Haraoui B, Buchbinder R, Hobby K, Roth JH, et al.
Dimensionality and clinical importance of pain and disability in hand osteoarthritis:
Development of the Australian/Canadian (AUSCAN) Osteoarthritis Hand Index.
Osteoarthritis Cartilage 2002;10:855–62.
25. Bellamy N, Campbell J, Haraoui B, Gerecz-Simon E, Buchbinder R, Hobby K, et al.
Clinimetric properties of the AUSCAN Osteoarthritis Hand Index: an evaluation of
reliability, validity and responsiveness. Osteoarthritis Cartilage 2002;10:863–9.
26. Slatkowsky-Christensen B, Kvien TK, Bellamy N. Performance of the Norwegian
version of AUSCAN – a disease-specific measure of hand osteoarthritis. Osteoarthritis
Cartilage 2005;13:561–7.
27. Niu J, Zhang Y, LaValley M, Chaisson CE, Aliabadi P, Felson DT. Symmetry and
clustering of symptomatic hand osteoarthritis in elderly men and women: the
Framingham Study. Rheumatology (Oxford) 2003;42:343–8.
28. Dougados M, Nakache JP, Gueguen A. Criteria for generalized and focal
osteoarthritis. Rev Rhum Engl Ed 1996;63:569–75.
29. Bellamy N, Buchanan WW, Goldsmith CH, Campbell J, Stitt LW. Validation study of
WOMAC: a health status instrument for measuring clinically important patient
relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the
hip or knee. J Rheumatol 1988;15:1833–40.
30. Saxne T, Lindell M, Mansson B, Petersson IF, Heinegard D. Inflammation is a feature
of the disease process in early knee joint osteoarthritis. Rheumatology (Oxford)
2003;42:903–4.
Extended report
Ann Rheum Dis 2008;67:942–948. doi:10.1136/ard.2007.074401 94731. Spector TD, Hart DJ, Nandra D, Doyle DV, Mackillop N, Gallimore JR, et al. Low-
level increases in serum C-reactive protein are present in early osteoarthritis of the
knee and predict progressive disease. Arthritis Rheum 1997;40:723–7.
32. Sharif M, Shepstone L, Elson CJ, Dieppe PA, Kirwan JR. Increased serum C reactive
protein may reflect events that precede radiographic progression in osteoarthritis of
the knee. Ann Rheum Dis 2000;59:71–4.
33. Pelletier JP, Martel-Pelletier J, Abramson SB. Osteoarthritis, an inflammatory
disease: potential implication for the selection of new therapeutic targets. Arthritis
Rheum 2001;44:1237–47.
34. RiksenNP, BarreraP, van denBroekPH, vanRielPL, Smits P, RongenGA.Methotrexate
modulates the kinetics of adenosine in humans in vivo. Ann Rheum Dis 2006;65:465–70.
35. Forrest CM, Stoy N, Stone TW, Harman G, Mackay GM, Oxford L, et al. Adenosine
and cytokine levels following treatment of rheumatoid arthritis with dipyridamole.
Rheumatol Int 2006;27:11–7.
36. Altman R, Brandt K, Hochberg M, Moskowitz R, Bellamy N, Bloch DA, et al. Design
and conduct of clinical trials in patients with osteoarthritis: recommendations from a
task force of the Osteoarthritis Research Society. Results from a workshop.
Osteoarthritis Cartilage 1996;4:217–43.
37. Bellamy N, Kirwan J, Boers M, Brooks P, Strand V, Tugwell P, et al.
Recommendations for a core set of outcome measures for future phase III clinical
trials in knee, hip, and hand osteoarthritis. Consensus development at OMERACT III.
J Rheumatol 1997;24:799–802.
38. Bellamy N. The WOMAC Knee and Hip Osteoarthritis Indices: development,
validation, globalization and influence on the development of the AUSCAN Hand
Osteoarthritis Indices. Clin Exp Rheumatol 2005;23:S148–3.
39. Allen KD, Jordan JM, Renner JB, Kraus VB. Validity, factor structure, and
clinical relevance of the AUSCAN Osteoarthritis Hand Index. Arthritis Rheum
2006;54:551–6.
40. Dreiser RL, Maheu E, Guillou GB, Caspard H, Grouin JM. Validation of an
algofunctional index for osteoarthritis of the hand. Rev Rhum Engl Ed
1995;62:43S–53S.
41. Leeb BF, Sautner J, Andel I, Rintelen B. SACRAH: a score for assessment and
quantification of chronic rheumatic affections of the hands. Rheumatology (Oxford)
2003;42:1173–8.
42. Theis JG, Deichsel G, Marshall S. Rapid development of tolerance to dipyridamole-
associated headaches. Br J Clin Pharmacol 1999;48:750–5.
BMJ Careers online re-launches
BMJ Careers online has re-launched to give you an even better online experience. You’ll still find our
online services such as jobs, courses and careers advice, but now they’re even easier to navigate and
quicker to find.
New features include:
c Job alerts – you tell us how often you want to hear from us with either daily or weekly alerts
c Refined keyword searching making it easier to find exactly what you want
c Contextual display – when you search for articles or courses we’ll automatically display job adverts
relevant to your search
c Recruiter logos linked directly to their organisation homepage – find out more about the company
before you apply
c RSS feeds now even easier to set up
Visit careers.bmj.com to find out more.
Extended report
948 Ann Rheum Dis 2008;67:942–948. doi:10.1136/ard.2007.074401